# **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

AirXpanders, Inc. (**Company**)

ABN

26 604 398 423

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	CHESS Depositary Interests (CDIs) (quoted) representing shares of Class A common stock of the Company (unquoted) (Shares)
2	Number of <sup>+</sup> securities issued or to be issued (if known) or maximum number which may be issued	26,536,500 CDIs (quoted) (representing 8,845,500 Shares (unquoted)) issued on 3 February 2017.
3	Principal terms of the <sup>+</sup> securities (e.g. if options, exercise price and expiry date; if partly paid <sup>+</sup> securities, the amount outstanding and due dates for payment; if <sup>+</sup> convertible securities, the conversion price and dates for conversion)	The CDIs were issued under the first of two tranches of a Placement announced to ASX on 27 January 2017 ( <b>Placement</b> ), on the same terms as the Company's existing CDIs. Three CDIs represent one Share.

4	<ul> <li>Do the <sup>+</sup>securities rank equally in all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</li> <li>If the additional <sup>+</sup>securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> </ul>	The CDIs will rank equally with the Company's existing CDIs, including in terms of the eligibility to participate in any dividends.
5	Issue price or consideration	Aso.92 per CDI
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ul> <li>The CDIs were issued pursuant to Tranche 1 of the Placement. The funds raised from the Placement will be primarily used by the Company for:</li> <li>Building inventory for US market;</li> <li>Acceleration of investment for US sales and marketing, including hiring of US sales force;</li> <li>Completion of commercial manufacturing transfer to Costa Rica and expanding capacity; and</li> <li>General working capital</li> </ul>
ба	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the</i> <sup>+</sup> <i>securities the subject of this Appendix</i> <sub>3</sub> <i>B</i> , and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	17 May 2016
6с	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	5,395,608 CDIs (quoted) issued on 3 February 2017 (representing 1,798,536 Shares)
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	21,140,892 CDIs (quoted) issued on 3 February 2017 (representing 7,046,964 Shares)
6e	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A

- 6f Number of <sup>+</sup>securities issued under N/A an exception in rule 7.2
- 6g If <sup>+</sup>securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the <sup>+</sup>issue date and both values. Include the source of the VWAP calculation.
- 6h If <sup>+</sup>securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 <sup>+</sup>Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

The CDIs were issued for A\$0.92 per CDI on 3 February 2017 which represents 81.2% of the 15 day VWAP (A\$1.1336 ) as calculated under rule 7.1A.3.

N/A

Rule 7.1: nil

Rule 7.1A: 13 Shares (equivalent to 39 CDIs)

Total: 13 Shares (equivalent to 39 CDIs)

3 February 2017

Number	and	+class	of	all
+securities				
(including t	he +s	securitie	s in se	ction
2 if applical	ole)			

Number	<sup>+</sup> Class
261,778,350 (assuming all issued Shares are held as CDIs, but excluding CDIs and Shares which are subject to ASX restrictions).	CHESS Depositary Interests (CDIs)

8

		Number	<sup>+</sup> Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	827,758 Shares *	ASX Restriction period - until 22 June 2017
		2,856,452 Options (to subscribe for a total of 2,856,452 Shares; equivalent to 8,569,356 CDIs)	Options – ASX Restriction period - until 22 June 2017
		2,499,250 Options ** (to subscribe for a total of 2,499,250 Shares; equivalent to 7,497,750 CDIs)	Options - not subject to ASX restriction
		469,970 warrants (to subscribe for a total of 469,970 Shares; equivalent to 1,409,910 CDIs).	Warrants

\* The equivalent of 2,483,274 CDIs are subject to ASX restrictions. (Each Share is represented by 3 CDIs.)

10	Dividend policy (in the case of a
	trust, distribution policy) on the
	increased capital (interests)

The Company does not expect to pay dividends in the foreseeable future.

#### Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the <sup>+</sup> securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
	-	
17	Policy for deciding entitlements in relation to fractions	N/A

18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to	N/A
24	brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security	N/A
25	holders' approval, the date of the meeting	17/1
26	Date entitlement and acceptance form	N/A
	and offer documents will be sent to persons entitled	
27	If the entity has issued options, and	N/A
27	the terms entitle option holders to participate on exercise, the date on	
	which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	N/A
		N7/4
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
21	How do security holders call part of	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker	

	and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of <sup>+</sup>securities (*tick one*)
- (a) Securities described in Part 1
- (b) All other <sup>+</sup>securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the <sup>+</sup> securities are <sup>+</sup> equity securities, the names of the 20 largest holders of the additional <sup>+</sup> securities, and the number and percentage of additional <sup>+</sup> securities held by those holders
36	If the <sup>+</sup> securities are <sup>+</sup> equity securities, a distribution schedule of the additional <sup>+</sup> securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional <sup>+</sup> securities

#### Entities that have ticked box 34(b)


- 38 Number of <sup>+</sup>securities for which <sup>+</sup>quotation is sought
- 39 <sup>+</sup>Class of <sup>+</sup>securities for which quotation is sought
- 40 Do the <sup>+</sup>securities rank equally in all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?

If the additional <sup>+</sup>securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)



#### **Quotation agreement**

42

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.

ities for which
rank equally in all
issue date with an
oted <sup>+</sup>securities?
securities do not
state:
nich they do
o which they
he next dividend,
of a trust,
interest payment
hich they do not
other than in
e next dividend,
nterest payment

- The issue of the <sup>+</sup>securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those <sup>+</sup>securities should not be granted <sup>+</sup>quotation.
- An offer of the  $\frac{1}{2}$  securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any <sup>+</sup>securities to be quoted and that no-one has any right to return any <sup>+</sup>securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

S, A. Com

Sign here: .....

Date: 3 February 2017

**Company Secretary** 

Print name: Brendan Case

== == == == ==

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from wh	Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	70,427,195 Shares (equivalent to 211,281,585 CDIs)		
Add the following:			
• Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	42,583 Options were exercised, resulting in the issue of 42,583 Shares as per Appendix 3B dated 20 January 2017 (equivalent to 127,749 CDIs)		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	-		
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>			
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
<i>Subtract</i> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	-		
"A"	70,469,778 Shares (equivalent to 211,409,334 CDIs)		

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	10,570,466 Shares (equivalent to 31,711,398 CDIs)	
Step 3: Calculate "C", the amount of placement used	t capacity under rule 7.1 that has already been	
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	8,771,930 Shares (not quoted) issued 15 June 2016 (equivalent to 26,315,790 CDIs (quoted))	
• Under an exception in rule 7.2	1,798,536 Shares (not quoted) issued 3 February 2017 (equivalent to 5,395,608 CDIs (quoted))	
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	10,570,466 Shares (equivalent to 31,711,398 CDIs)	
Step 4: Subtract "C" from ["A" x "B"] to calcul 7.1	ate remaining placement capacity under rule	
"A" x 0.15	10,570,466 Shares (equivalent to 31,711,398 CDIs)	
Note: number must be same as shown in Step 2		
Subtract "C"	10,570,466 Shares (equivalent to 31,711,398 CDIs)	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	-	
	[Note: this is the remaining placement capacity under rule 7.1]	

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
" <b>A</b> "	70,469,778 Shares (equivalent to 211,409,334 CDIs)	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	7,046,977 Shares (equivalent to 21,140,931 CDIs)	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	7,046,964 Shares (not quoted) issued 3 February 2017 (equivalent to 21,140,892 CDIs (quoted))	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	7,046,964 Shares (not quoted) (equivalent to 21,140,892 CDIs (quoted))	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	7,046,977 Shares (equivalent to 21,140,931 CDIs)
Note: number must be same as shown in Step 2	
<i>Subtract</i> "E" Note: number must be same as shown in Step 3	7,046,964 Shares (not quoted) (equivalent to 21,140,892 CDIs (quoted))
<i>Total</i> ["A" x 0.10] – "E"	13 Shares (equivalent to 39 CDIs) Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.